Masakazu Kakuni
Directeur/Membre du Conseil chez PHOENIXBIO CO., LTD.
Profil
Masakazu Kakuni has held the following positions in his career: Director at PhoenixBio Co., Ltd.
since 2005, and President at KMT Hepatech, Inc. since 2020.
Postes actifs de Masakazu Kakuni
| Sociétés | Poste | Début |
|---|---|---|
| PHOENIXBIO CO., LTD. | Directeur/Membre du Conseil | 01/06/2014 |
KMT Hepatech, Inc.
 KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | President | 01/12/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHOENIXBIO CO., LTD. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | Commercial Services |